Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Employees - 28,
CEO - Wayne F. Pisano,
Sector - Healthcare,
Country - CA,
Market Cap -
Altman ZScore(max is 10): -36.09, Piotroski Score(max is 10): 1, Working Capital: $12719000, Total Assets: $19702000, Retained Earnings: $-484400000, EBIT: -33255000, Total Liabilities: $13208000, Revenue: $0
AryaFin Target Price - $0.14 - Current Price $ - Analyst Target Price $
Ticker | ONCY |
Index | |
Curent Price | |
Change | |
Market Cap | |
Average Volume | |
Income | |
Sales | |
Book Value/Share | |
Cash/Share | |
Dividend Est | |
Dividend TTM | |
Dividend Ex-Date | |
Employees | |
Moving Avg 20days | |
Moving Avg 50days | |
Moving Avg 200days | |
Shares Outstanding | |
Earnings Date | |
Inst. Ownership |
Price/Earnings | |
Forwad P/E | |
PE Growth | |
Price/Sales | |
Price/Book | |
Price/Cash | |
Price/FCF | |
Quick Ratio | |
Current Ratio | |
Debt/Equity | |
Return on Assets | |
Return on Equity | |
Return on Investment | |
Gross Margin | |
Ops Margin | |
Profit Margin | |
RSI | |
BETA(β) | |
From 52week Low | |
From 52week High |
EPS | |
EPS next Year | |
EPS next Qtr | |
EPS this Year | |
EPS next 5 Year | |
EPS past 5 Year | |
Sales past 5 Year | |
EPS Y/Y | |
Sales Y/Y | |
EPS Q/Q | |
Sales Q/Q | |
Sales Surprise | |
EPS Surprise | |
ATR(14) | |
Perf Week | |
Perf Month | |
Perf Quarter | |
Perf Year | |
Perf YTD | |
Target Price |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer